AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating reiterated by Jefferies Financial Group in a research note issued on Wednesday, Digital Look reports. They presently have a £175 price target on the biopharmaceutical company’s stock. Jefferies Financial Group‘s price objective would suggest a potential upside of 27.75% from the stock’s previous close.
Several other research analysts have also recently weighed in on the stock. Royal Bank Of Canada started coverage on shares of AstraZeneca in a research note on Tuesday, September 8th. They set an “outperform” rating and a £145 price target on the stock. Deutsche Bank boosted their price objective on shares of AstraZeneca from £117 to £120 and gave the company a “hold” rating in a research report on Friday, November 6th. Citigroup upped their price objective on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a £175 target price on shares of AstraZeneca in a report on Wednesday, October 7th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of £155.50.
Get Our Latest Stock Report on AZN
AstraZeneca Stock Performance
Shares of LON AZN opened at £136.98 on Wednesday. AstraZeneca has a 12-month low of £114.04 and a 12-month high of £157.32. The firm has a market capitalization of £212.45 billion, a price-to-earnings ratio of 19.40, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The company has a current ratio of 1.01, a quick ratio of 0.59 and a debt-to-equity ratio of 66.10. The firm has a 50 day moving average of £127.50 and a 200 day moving average of £134.41.
Insider Buying and Selling at AstraZeneca
In related news, insider Michel Demare acquired 2,500 shares of the stock in a transaction dated Monday, September 14th. The shares were purchased at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is currently owned by insiders.
AstraZeneca Company Profile
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Further Reading
- Five stocks we like better than AstraZeneca
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
